Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, presents initial results from the Phase I dose-escalation study (NCT04775745) of LP-168, a novel next-generation BTK inhibitor that can bind wild-type and C481-mutated BTK covalently and non-covalently, respectively, with preclinical activity in resistant chronic lymphocytic leukemia (CLL) models. Doses ranging from 100-300mg daily and 150mg twice daily were examined, with 200mg and 300mg daily identified as well-tolerated and showing preliminary efficacy. These doses are recommended for further evaluation in Phase II trials. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
8 дек 2023
